Prevexxion RN is composed of a serotype-1 construct vaccine which Boehringer says offers a unique balance between safety and efficacy against the most virulent types of Marek’s disease virus strains.
Prevexxion RN+HVT+IBD is a solution combining Prevexxion RN and Vaxxitek HVT+IBD in one ampoule. It is designed to meet the needs of customers in long-life bird segments with protection from the hatchery.
Prevexxion RN vaccines are available in ampoules of 1000, 2000, and 4000 doses, frozen in liquid nitrogen.
Jerôme Baudon, Head of Poultry at Boehringer Ingelheim, said: “Our Prevexxion RN range provides value through innovation to Marek sensitive poultry producers looking for continuous live production productivity improvement and effective protection. Field and lab experiments conducted worldwide demonstrated its safety, efficacy and its strong, early, and long-lasting protection through the lifespan of the birds and against very virulent Marek’s disease challenge.
Prevexxion RN is the new golden standard for Marek's disease vaccination programs2”.
For more information, contact your Boehringer Ingelheim representative.
Reference
Intervet/Schering-Plough Animal Health has launched a new oxytetracycline spray which the company says offers more accurate antibiotic delivery whether the can is used in an upright or inverted position.
Alasdair King MRCVS, Intervet/Schering-Plough Animal Health veterinary manager, says new Engemycin Spray has been developed specifically to address problems reported with traditional aerosol cans:
"Antibiotic sprays are used widely, yet they can become a practical nuisance to both vets and farmers simply because many cans do not perform satisfactorily. All too frequently the nozzle leaks or detaches, the spray pattern is irregular - particularly if the can is held upside down as it so often needs to be - or the valve clogs before the can is empty. This can be a source of great frustration to users, but new Engemycin Spray overcomes all these problems."
Intervet/Schering Plough says Engemycin Spray combines a unique, quick-drying formulation with an innovative, non-clogging spray valve. The quick-drying formulation minimises wastage from the sprayed area, while the new valve - which works as well when the can is upside down - cuts spraying time and ensures more reliable and constant delivery of antibiotic. The valve is unique and designed to enable the can to fully empty.
Engemycin Spray is licensed for the treatment of foot and wound infections in cattle, sheep or pigs following surgery or physical injury. The new product is available now from wholesalers.
Thermo-insulated wellington boots to keep feet warm on farms during winter time are being launched by Bekina of Belgium in the UK and ROI.
Like the Bekina Steplite X boots designed for general farm work, the Thermolite cold weather wellie is moulded from polyurethane rather than traditional rubber or PVC. However, the Thermolite wellie also has extra thick uppers and soles, making them suitable for use by farmers and vets in temperatures down to minus 40C.
Wide fitting for extra comfort, Bekina Thermolites are supplied with a free pair of removable, insulated insoles. They are also available with safety toecaps.
For details Freephone AgriHealth 0800 731 2490,or visit http://www.bekina.be/
Bovilis Bovivac S is used for active immunisation to induce serological and colostral antibody production against Salmonella Dublin and Salmonella Typhimurium.
In the face of an outbreak, it can also be used to reduce Salmonella Typhimurium infections when used as part of an overall herd management programme.
MSD says Bovilis Bovivac S may also contribute to reducing S. Typhimurium contamination of the environment. Other than the packaging, the vaccine itself is identical.
Lucy and Rosanna have joined the business in hybrid positions as Novice OVs and will do this alongside working in a clinical practice.
The company says this is a significant milestone for the industry, which has relied on overseas talent for many years.
Eville & Jones says it has now developed a compelling proposition for UK new graduates who want to combine OV work with traditional clinical practice, and vets looking for a lifestyle change or a move away from practice, working flexibly in export certification, abattoir work, certification against standards, or small animal vaccination.
Charles Hartwell, chief executive officer of Eville & Jones said: “The team at Eville & Jones has spent two years developing an attractive proposition to encourage UK-educated veterinary surgeons to consider a career in this field, whether combined with traditional clinical practice, or stand alone.
"We wish Lucy and Rosanna the best of luck and hope they become trailblazers for many others to follow in their footsteps.”
Lucy said: “I’m really excited to be starting my career in veterinary public health where, as an OV, you can positively affect the lives of 1000’s of animals."
Rosanna added: “I’m really proud to have joined the veterinary industry this summer; OVs are instrumental in monitoring and safe-guarding animal welfare in a way that many vets don't realise."
The awards celebrate the achievements of remarkable people who dedicate their lives to improving animal health and welfare both in the UK and abroad. They are open to vets, vet nurses, farmers, animal welfare professionals and animal welfare teams who can be nominated to receive an award by fellow peers, friends and family or the general public.
There are nine nomination categories including a new one this year to recognise an international individual or team that stands out from the crowd by influencing and significantly contributing to making a visible difference in the world of animal welfare.
The categories are:
Chris Laurence Vet of the Year supported by Vet Record.
Vet Nurse of the Year supported by Agria Pet Insurance
Charity Team of the Year supported by PDSA
Charitable Contribution of the Year supported by Blue Cross
International Cat Care Welfare of the Year supported by International Cat Care
Farmer of the Year supported by R.A.B.I. and Farmers Guardian
Farm Educator of the Year supported by NADIS and Farmers Guardian
Outstanding Contribution to Animal Welfare supported by Your Dog and Your Cat magazines
Outstanding International Contribution to Animal Welfare supported by Ceva International
Nominations can be made at https://www.cevawelfare.com/click-here-to-nominate with nominations closing on Tuesday 31 December 2019.
Finalists will be announced at the beginning of February and winners will be revealed at an awards ceremony in Birmingham in April on the eve of BSAVA Congress.
Cuneyt Seckin, Managing Director of Ceva Animal Health UK and Ireland, said: "As an animal health company, animal welfare is a huge focus for us. The Ceva Animal Welfare Awards are an opportunity to formally recognise and congratulate outstanding animal welfare teams and individuals who contribute to the protection and welfare of animals in their daily lives."
For more information, visit www.cevawelfare.com.
Animalcare Ltd has launched Tilmodil (tilmicosin 300mg/ml solution for injection), a semi-synthetic macrolide antibiotic licensed for pneumonia in cattle and sheep, foul in the foot in cattle, and footrot and mastitis in sheep.
According to the company, Tilmicosin is fast-acting1, long-acting2 and highly effective against the major Gram-ve bovine respiratory pathogens.2,3 In addition, the company says tissue penetration is excellent.1 In calves a single SC injection at 10mg/kg bw results in lung concentrations exceeding the MIC90 of Mannheimia haemolytica for 72 hours.2
Animalcare says that pooled data from greater than 6000 cattle has confirmed the effectiveness of tilmicosin in the treatment of bovine respiratory disease (BRD) in well-controlled, randomised field studies. Tilmodil treatment has been proven equally effective compared to antibiotics, such as florfenicol, marbofloxacin and danofloxacin.
A recent report by the Farm Animal Welfare Council estimates that three million of the national sheep flock are lame at any one time. It is estimated that footrot is responsible for greater than 90% of lameness and is present in 97% of flocks. Tilmicosin has good activity against the key Gram-ve pathogens2 and has been successfully used in the treatment of footrot.4
Tilmodil has been developed for animal use only and is administered by veterinary surgeons only. Dosage is 1ml per 30kg bw for respiratory disease and mastitis in sheep and 0.5ml per 30kg bw for interdigital necrobacillosis (foul in the foot/footrot/bovine pododermatitis).
Tilmodil is administered as a single, low volume subcutaneous (SC) injection dose and presented in 50ml multi-dose vials.
References
1. Apley M., Antimicrobial therapy of Bovine Respiratory Disease.Veterinary Clinics of North America.Food Animal Practice (1997) 13,3:159-5622. Tilmodil SPC3. Giguere S et al .,Antimicrobial therapy in Veterinary Medicine.4th edition 2006.Chp.12,2014. Winter A., Lameness in sheep. 2. Treatment and control. In Practice (2004),3, 130-139.
James Hutchings, Head of Sales for Bimeda UK, said: "The launch of Tetroxy Vet highlights our ongoing commitment to providing UK veterinarians with a choice of high quality veterinary pharmaceuticals at a fair price."
Bimeda says the benefits of Tetroxy Vet include:
Tetroxy Vet is available in a 100ml pack size.
Titled 'Animal Welfare For The Many, Not The Few' (uh?), the policy proposes appointing an Animal Welfare Commissioner to ensure Government policy across Whitehall is informed by the latest scientific evidence on animal sentience.
The proposed policies in the document include a number of things the Conservatives have already been working on, such as:
Prohibiting the third party sale of puppies. All puppies will need to be sold with their mother on site.
Increasing maximum sentences for those convicted of animal cruelty.
Introducing mandatory CCTV in all slaughterhouses.
Enshrining the principle of animal sentience in law, covering all policy areas to prevent practices that expose animals to cruel and degrading treatment.
Introducing a ban on ivory trading.
However, Labour propose a number of additional ideas which are now open for a public consultation, including:
Improving accessibility to vets for those on low incomes/receiving financial support, working with organisations like the PDSA to explore how access to affordable vet care can be expanded.
Banning the use of animal shock collars, including sale and importation.
Expanding mandatory microchipping to cats.
Consulting with landlords and tenants on the ability for tenants to keep pets as default unless there is evidence that the animal is causing a nuisance.
Ending the badger cull.
Strengthening the Hunting Act, closing loopholes that allow for illegal hunting of foxes and hares.
Banning Foie Gras (which the Conservatives say is impossible under EU rules which Labour has said it wishes to continue following post-Brexit)
Mandatory labelling of domestic and imported meat, including country of origin, method of production and slaughter (stun or non-stun)
Requiring motorists to report accidents where an animal has been injured.
Banning wild animals in circuses.
Sue Hayman MP, Labour’s Shadow Environment Secretary, said: "Labour is the party of animal welfare. From bringing in the ban on fox hunting to tightening the rules on the transport of live animals, Labour has always been consistent in our leadership on matters of animal welfare.
"Today we’re making proposals for real, long-term progress. Our vision is one where no animal is made to suffer unnecessary pain and we continue to drive up standards and practice in line with the most recent advances and understanding."
Conservative MP Steve Double said: "Labour are belatedly playing catch-up with the huge progress made by this Government on animal welfare.
However, Labour wouldn’t even be able to deliver some of these promises because they want to keep following EU rules after Brexit.
From introducing mandatory CCTV into slaughter houses to increasing the maximum sentence for animal cruelty ten-fold, the Conservatives will continue taking the action needed to ensure animals receive the proper protection they deserve."
Elanco Animal Health has announced that there have been extensions to the withdrawal periods for Dectomax (doramectin) 10 mg/ml Solution for Injection and Micotil (tilmicosin) 300 mg/ml Solution for Injection.
For Dectomax injectable, meat withdrawal for cattle and sheep will be extended to 70 days and pigs to 77 days. For Micotil, sheep milk withdrawal will be extended to 18 days and milk from cows during the dry period or from pregnant heifers should not be used for human consumption until 36 days after calving.
Elanco is reminding veterinary surgeons and SQPs that they may continue to prescribe according to the current label but it is good practice to implement revised withdrawal periods. The company is also taking this opportunity to highlight the importance of getting into the habit of double-checking withdrawal periods when administering drugs, because they do change from time to time in the light of new knowledge.
Norbrook has announced the re-launch of its range of intramammary tubes for lactating and dry cows, to promote holistic herd health and responsible use of antimicrobials.
The company’s range, which includes products across a number of antibiotic classes, primarily targets clinical cases of mastitis in lactating cows, and removal or prevention of infection around the dry period.
Chris Geddes MRCVS, Marketing Manager at Norbrook, says the re-launch is focused on modernising the range and making it clearer for practice staff and farmers to avoid confusion between lactating cow and dry cow products: “We have a wide range of 11 products containing a variety of antimicrobials: for example Duofast is the only lactating cow product to contain trimethoprim and sulfadiazine. We are working with vets to promote responsible use by farmers, for example through the use of our teat sealant Noroseal for Selective Dry Cow Therapy."
The full range includes Duofast, Lactaclox, Cefimam LC, Combiclav, Noroclav and Multiject for the lactating cow; Cefimam DC, Noroclox, Bovaclox and Bovaclox DC Xtra for the dry cow; and teat sealant Noroseal.
Norbrook has also produced a best practice guide to mastitis control, available for vets in English and Polish, which can be shared with farmers.
Chris added: "We recognise the need to reduce overall use of antimicrobials, especially for disease prevention – as well as using non-antimicrobial products such as teat sealants. These practices, together with the recent focus on using older classes of antimicrobials, mean that as an industry we need to adopt a holistic and targeted approach to herd health management.
"We believe that by providing additional information to aid with prevention of disease, and re-launching our intramammary range to make it clearer when products should be used, we can help to achieve that."
Norbrook says the full range of products is in stock, but some wholesalers may hold components of the old range as the new range is phased in.
The app, which works on tablets and smartphones, allows vets to e-mail audit results directly to clients following an interactive calf health assessment at the farm.
MSD Animal Health’s youngstock marketing manager Robert Simpson said: “Our new app allows both parties to explore, record and score calf health performance across five core areas to identify the strengths and weaknesses of any rearing unit’s environment and processes.
“Working through a series of 10 questions within each core area – designed to tease out where a rearing unit is in terms of accepted best management practice – allows vet and farmer to quickly pinpoint any areas needing attention.
"What’s more, repeating the checklist every six or 12 months is a great way to keep things on track, allowing both parties to monitor progress against agreed targets”.
For more information about the app, contact your MSD account manager.
1,300 veterinary surgeons responded to the BVA survey, which was carried out in July. They were asked what Official Controls Qualification (OCQ) they hold or have held in the past, and give reasons for dropping a previously held qualification or choosing not to revalidate.
According to the BVA, many respondents criticised the current training and revalidation process, which is administered by Improve International on behalf of the Animal and Plant Health Agency (APHA).
Factors including time, the cumulative cost of renewing each module at regular intervals, a lack of relevance and duplication of learning across different modules were all cited as reasons for choosing to drop qualifications.
25% of vets who currently hold the Essential Skills OCQ say they are planning not to renew the qualification, with 67% saying it is because of the expiry of grandfather rights and 66% saying it is because they find the requirements too onerous.
18% of those who currently hold the Tuberculin Testing OCQ are not planning on renewing, either because they are finding the revalidation requirements too onerous (58%), too expensive (42%) or because the work is not sufficiently rewarding (42%).
35% of those who hold the Statutory Surveillance OCQ are not planning on renewing, primarily because of overly onerous revalidation requirements.
The largest drop off is predicted amongst holders of the Exports OCQ, 38.4% of whom said they plan not to revalidate.
Amongst the species bolt-ons, 45.5% of the holders of the Small Animal Exports OCQ, 51% of the Ungulate Exports OCQ, 66% of the Equine Exports OCQ, 72.5% of the Avian Exports OCQ, 47% of the Product Exports OCQ, 68% of the Germinal Products Exports OCQ and 32% of the Companion Animals OCQ said they plan not to renew, either because of the expiry of grandfather rights, or the expense or, in the case of Ungulate Exports, because revalidation is too onerous.
In the current system equine exports are included in the ungulate export OCQ, which the BVA says was a concern for those vets who only work with farm animals. APHA and Improve International have helpfully introduced an equine-only OCQ for exports that better meets the needs of equine-only vets.
BVA reports that it has had a positive meeting with APHA to discuss the survey results and explore practical solutions to iron out issues with the current system and make it easier to use. As a next step, BVA has agreed to review the modules and make recommendations for improving the structure of training and the revalidation process.
BVA President John Fishwick said: "The unprecedented response rate to this survey really hits home the strength of feeling on this issue. There is an urgent need to review and improve the revalidation process to safeguard against capacity and capability issues in this critical section of the workforce.
"It’s really positive that APHA recognises that there are issues with the current system and is keen to work with us to make it more proportionate and fit for purpose while continuing to maintain high standards. It’s more important than ever to retain skilled professionals so that the workforce is at full strength to respond robustly to disease outbreaks and meet demand for export certification after Brexit."
Andrew Soldan, APHA Veterinary Director said: "The integrity of our official controls and export certification is vitally important. The Official Controls Qualifications are a key part of this as they provide standardised OV training as well as assurance of high standards. I’m grateful to BVA for their assistance as we look to make further improvements to the system in the future."
The plans developed by the Animal and Plant Health Agency (APHA), an agency of the Department for Environment, Food & Rural Affairs (DEFRA), involved the creation of a new role of Certification Support Officers (CSOs), non-veterinarians who would support the work of Official Veterinarians (OVs) in the signing of export health certificates for products of animal origin such as meat, dairy, processed products and animal by-products.
The proposals for the creation of CSOs by APHA has arisen due to concerns about the growth of exports in recent years and the potential for an up to 300% increase in products requiring OV certification if the UK has to certify exports of products of animal origin to the EU once the UK leaves the EU. Under APHA’s plans CSOs will work under the direction of veterinary surgeons and support their certification work (for example, verifying temperature checks), although the final certification will always need to be signed by OVs. The role will not involve certification relating to live animals or germinal products.
At the RCVS Council meeting on Thursday 1 November 2018 Council members agreed to facilitate APHA’s proposals and to make changes to the RCVS requirements so as to allow CSOs to support OVs in their certification work.
Amanda Boag, RCVS President, said: "As we have stated in our recent statement on ‘no-deal’ Brexit, it has been estimated that there would be 325% increase in veterinary certification requirements if the UK leaves the EU without a deal, and with these proposals Defra and APHA are preparing for this by increasing the support available for Official Veterinarians. Furthermore the proposal is in line with the concept of a vet-led team, with veterinary surgeons focusing on tasks only vets can do, whilst delegating some tasks to suitably trained and quality-assured members of our teams.
"We appreciate that there were some concerns over the level of education and training required by CSOs and are glad that the APHA has accommodated those views by increasing the level of education to three A-Levels (or equivalent in Scotland) and clarifying the nature of the training required by CSOs.
"By signalling its support for the proposals, RCVS Council has been assured that the integrity and value of the veterinary signature will be upheld and we are glad that we can play a key role in helping the veterinary profession prepare the UK for leaving the EU."
The RCVS position statement on the potential impact of a ‘no-deal’ Brexit scenario is available at www.rcvs.org.uk/brexit
Severn Edge was formed six years ago with the merger of two long-standing neighbouring practices, and now employs 135 people, including 43 veterinary surgeons.
Mrs Karyn MacKenzie, Director of CVS’ Practice Division, said: "Severn Edge is an impressive practice with an outstanding leadership team and an ambitious and exciting vision for the future which we share. We are delighted to welcome the team to CVS and look forward to working with them to help them build an even more successful future."
Dr John Brentnall BVSc MRCVS, a Director of Severn Edge, will continue in the role of CVS Regional Director. He said: "It was clear from our early discussions that CVS understood what we are trying to achieve. We have embarked on a significant investment programme, including upgrading our surgery at Madeley outside Telford, and the redevelopment of the site of an additional clinic which we have recently acquired in Craven Arms.
"In order for us to continually upgrade our clinics, provide the widest range of career opportunities for our staff and steer our practice through an increasingly competitive world, we believe that the best interests of us all lie in joining forces with CVS. It is known for its interest in equine and farm practice, as well as companion animal practice, and has a policy of significant investment in both infrastructure and staff. We believe it offers the best fit with Severn Edge."
Charcovet Gel contains 30g of activated charcoal in a 60ml syringe.
Dr John Henderson, Large Animal Product Manager at Forte Healthcare said: “In young animals with digestive disturbances, Charcovet Gel uses the adsorbent properties of activated charcoal to support the gut in a return to normal function.
"The value of using activated charcoal in cases of digestive upset in young animals has long been recognised, but the difficulty and mess involved in mixing such a fine dry powder in water presented considerable usability issues.
"With Charcovet Gel, the appropriate volume of activated charcoal gel is simply selected from the graduated syringe and administered directly into the animal’s mouth.
"Charcovet Gel can be given daily as needed to support the animal during the period of digestive upset.”
Each box of Charcovet Gel contains 12 syringes.
Charcovet Gel is available now from all major veterinary wholesalers, or directly from Forte Healthcare Ltd.
For more information contact your Forte Territory Manager, email enquiries@fortehealthcare.com or visit: https://www.fortehealthcare.com/product/charcovet-gel
Eurovet Animal Health has launched a new product, Bovocycline 2000 mg pessary for cattle.
Bovocycline 2000 is the only veterinary licenced antibiotic pessary for the treatment of retained foetal membranes in cattle. It is licenced for the treatment of post parturient disorders in cattle, for administration after dystocia, retained foetal membranes (RFMs) and endometritis.
According to Eurovet, the incidence of retained foetal membranes in cows varies from zero to 25 per cent, but the average is around 4 per cent in most herds. RFMs result in reduced cow fertility and a higher risk of culling due to poor fertility. Pessaries are still considered the preferred treatment for vulval discharges in cattle by farmers.
Ruth Vernon, Technical Services Manager for Eurovet said: "The control of post partum problems in cattle is rarely straight forward, but it is great to have a veterinary licensed treatment designed specifically for this purpose, in one pessary that contains 2000mgs tetracycline".
For more information please contact Eurovet Animal Health. Tel: 01223 257933. E-mail: office@eurovet-ah.co.uk www.eurovet-ah.co.uk
The trial, which was conducted by a UK-French team of researchers from PBD Biotech and Biosellal, is being presented at the European Association of Veterinary Laboratory Diagnosticians (EAVLD) Congress in Brussels today.
Current tests only allow the reliable detection of Mycobacterium avium subspecies paratuberculosis (MAP) from 18-24 month calves and are unable to distinguish between active and passive infection.
For the 16-month trial, calves from three different herds and born from MAP-positive and MAP-negative cows were tested monthly using PBD Biotech’s Actiphage Rapid kit and Biosellal’s Bio-T kit MAP PCR on blood samples, and the same PCR on faeces.
Researchers say the trial proves that early detection of live MAP infection is possible, and paves the way for improved Johne’s disease monitoring and control measures on farms.
Co-Author Dr Ben Swift, Research Fellow in Antimicrobial Resistance at the Royal Veterinary College and R&D Director at PBD Biotech, said: "Young animals are highly susceptible to infection and being able to identify Johne’s disease at this early stage is key to controlling disease spread.
The trial showed that the sensitivity and specificity of Actiphage enables detection of lower levels of MAP than the current culture methods, and provides results in 6 hours rather than weeks."
The Actiphage Rapid technology used in the trial identified live MAP infection at least 4 weeks’ earlier than the faecal PCR in 75% of cases: in one case, the new diagnostic detected MAP in the blood of a one-day old calf born from a MAP-positive cow.
Claire Pelletier, Directrice Générale of BioDev, consultant to Biosellal, will be presenting findings from the trial, which also showed the transient nature of the infection. She said: "The study showed that two calves, identified as MAP-positive by Actiphage-PCR on blood during the first monthly sampling didn’t shed MAP into their faeces until 10 and 11 months. This emphasises that early detection provides a short window of time that allow for control of the disease."
Other international trials using Actiphage are underway to investigate the presence of MAP in milk.
In 2014 ioLight co-founders, Oxford physicists Andrew Monk and Richard Williams, filed a patent application for a pocket-sized digital microscope with a performance that compares with expensive laboratory microscopes. They asked Cambridge Industrial Design to realise the product, briefing them that the device would need to deliver images with one micron resolution (required to view human or animal cells) onto a smartphone or tablet, be pocket-sized, easy to use, and economical to build in medium to high volumes.
One of the biggest challenges was in making the unit pocket-sized, which meant it had to be foldable, something which could have led to a loss in the rigidity needed to achieve high resolution images. This challenge was overcome with the use of a single hinge which the company says makes the ioLight both portable and robust.
Alex Jones, Managing director of Cambridge Industrial Design said: "We recognised immediately this was a great idea but the design brief was certainly a challenge. Fortunately, challenges can sometimes bring out the best in designers. The final design is a real success both aesthetically and ergonomically, and this award is a fantastic acknowledgement for the design process and the final product that we have created together with ioLight."
ioLight is also celebrating another success: closing its second round of equity funding after raising £320k from 335 investors on the Crowdcube platform (128% of the initial target).
The company says the new funding will allow it to promote the microscope to a wide range of target markets including veterinary surgeons, education, laboratory and field research, museums and public engagement as well as to international markets.
Andrew Monk, ioLight’s co-founder said: "The product is so simple to use that it is the ideal communication tool for explaining science to the public, students and customers. The microscope lets everyone see the same image so the discussion is about the picture not the tools. It’s a perfect fit for government public engagement campaigns, which are well funded at the moment. We are absolutely delighted that this funding provides us with the opportunity for both product development and to reach out and make microscopy available to so many more people."
Velactis (cabergoline) is a POM marketed by Ceva Animal Health, used in the herd management programme of dairy cows as an aid in abrupt drying-off, by reducing milk production.
The product was authorised through the European Medicines Agency (EMA) in December 2015 and was first sold in the UK in April 2016.
The VMD says it has been made aware of reports of serious adverse events, predominantly occurring in Denmark, involving recumbency (lying down and unable to rise) and some deaths. Most adverse events occurred within 8 to 24 hours following product administration. Anecdotal evidence suggests that hypocalcaemia treatments may be successful in reversing clinical signs.
Ceva has decided to stop further distribution of the product in Europe voluntarily, pending the outcome of further investigations to assess a possible causal link between the product and the adverse events reported.
The VMD, EMA, other agencies throughout Europe and the MAH are working closely to monitor the situation.
The VMD highlights that due to the nature and use of the product there is no risk to human health or consumer safety.
Vets and dairy farmers are strongly encouraged to report any adverse events associated with use of Velactis to the VMD using its online reporting form or directly to Ceva for further investigation by the MAH as necessary.
Grahame Gardner has introduced the M559, a classically styled tunic, stocked for the first time in bottle green.
The company says that although it has sold numerous ladies tunics in bottle green, this is the first time it has stocked a male tunic in the characteristic veterinary colour.
The M559 incorporates side fastening with the option of contrasting epaulettes, alongside practical pockets and side slits.
Simon Ward, Sales Director said: "We are delighted to introduce this new garment to the veterinary market. We are continually reviewing our range in response to customer comments, and felt it was time we stocked a bottle green option, specifically for male members of the veterinary team."
Stocked in sizes from 34" to 50" (chest), the M559 is just one of several new styles introduced in Grahame Gardner's latest brochure. The company is also launching a new men's scrub tunic. The SS3295 has a v style neck, complemented by the v-detail on the sleeves, and contrasting trim available on the neck, sleeve and pocket. Also stocked in bottle green, the company says this tunic is aimed at veterinary professionals who prefer a more relaxed approach to uniforms.
To explore Grahame Gardner's collection please take a look at http://www.grahamegardner.co.uk/, or call 0116 255 6326 to order a copy of their new brochure.
Dunlops has changed its name to Henry Schein Animal Health.
David Hinton, Managing Director said: "As we change our name to Henry Schein Animal Health, we also reaffirm our company's strong commitment to offer a comprehensive array of products and services to help animal health practitioners in the United Kingdom operate more efficient and successful practices, and provide the best quality patient care.
"We have a new name, but we have the same strong team, the same values, and the same dedication to providing excellent service to our customers."
Henry Schein Animal Health’s expanded offerings include VetLink and Thrive. VetLink is a new e-commerce web site system that enables veterinary surgeons to access the growing internet sector, allowing you to sell anything from pet prescriptions to accessories online, to be delivered to your customers’ homes by Henry Schein Animal Health. Thrive is a new veterinary business analysis service that integrates with practice management software to use a Key Performance Indicator based approach that provides insight into a your practice and identifies areas where you can enhance your business.
Eurovet Animal Health Ltd has entered the UK veterinary pharmaceuticals market with a portfolio of products including a levothyroxine tablet for the treatment of canine hypothyroidism, injectables for cattle and pigs, a xylazine injection for use in cattle, horses, dogs & cats and a corticosteroid for use in horses, cattle, pigs, cats and dogs.
Eurovet Animal Health is a subsidiary of Dutch company, AUV, which was established in 1969 as a cooperative by 100 veterinary surgeons, and is now jointly owned by 2000 vets. The company says this gives it a unique perspective on the products that veterinary surgeons really need and want. And whilst Eurovet Animal Health is still relatively small in the UK, the parent company Eurovet Animal Health BV owns state-of-the-art manufacturing facilities and provides access to international expertise, support and resources.
Eurovet Animal Health Ltd will be offering Eurovet products previously distributed by partner companies in the UK, so vets can expect to see brands they know and trust, as well as new brands. Existing products will be available from veterinary wholesalers and include:
Further information about Eurovet's range of products is available from Eurovet Animal Health, Compass House, Chivers Way, Histon, Cambridge, CB24 9AD Tel: 01223 257933 E-mail office@eurovet-ah.co.uk http://www.eurovet-ah.co.uk/
Novartis Animal Health has been found in breach of the National Office of Animal Health Code on promotion.
The complaint related to a promotion at the National Sheep Association's 'Scotsheep 2012' on 6 June 2012, where Novartis had used the strapline 'Zolvix - the World's most effective wormer'.
The NOAH Committee unanimously took the view that the phrase constituted an all-embracing claim and a superlative which could not be substantiated.
Accordingly, the Committee found the promotion in breach of Clause 5.2.
The full details of the NOAH Committee's rulings is published on the NOAH website at www.noah.co.uk/code. The full report of this particular case will be available shortl.
The recognition, management and treatment of pain in calves was identified by the BVA and the BCVA as a priority animal welfare problem following the launch of the BVA’s Animal welfare strategy last year, with the two organisations working closely together to progress an evidence-based best practice position and set of recommendations for the profession.
The new position statement specifically recommends the use of non-steroidal anti-inflammatory drugs (NSAIDs) in addition to local anaesthesia when conducting disbudding and castration in calves, as these are procedures that have been shown to cause acute pain at the time of the procedure and chronic pain afterwards. Analgesics have been shown to reduce the signs of pain in this post-operative period in a wide range of research studies.
The position also recommends the 'Three Rs' approach to castration and disbudding of calves, advocating that, where possible, these procedures are: Replaced by, for example, selecting polled sires to replace disbudding; Reduced by, for example, appropriate use of sexed semen to reduce the number of male calves requiring castration; or Refined, with the use of analgesics.
BVA President Gudrun Ravetz said: "BVA and BCVA’s joint position further reinforces the profession’s focus as animal welfare advocates, and conveys the need for adequate pain management that is reflective of current scientific understanding of pain recognition and treatment in cattle.
"Existing legislation requires a level of anaesthesia and we would encourage veterinary colleagues and stock-keepers to also discuss appropriate analgesic regimes used so that vets prescribe appropriately licensed NSAIDs and other analgesic medicines as required, as part of ensuring a good life for the animals we farm for food."
The recommendations support the University of Nottingham School of Veterinary Medicine and Science’s study, published yesterday in the Veterinary Record, which has found that calf husbandry procedures were significantly less likely to include the use of analgesics in addition to the local anaesthetic (that is routinely used) for other similarly painful procedures. While local anaesthesia can reduce or eliminate much of the acute pain, chronic pain may still remain once the relatively short duration of local anaesthetic action wanes.
John Remnant, a member of BCVA Board and Clinical Assistant Professor in Farm Animal Health and Production at the Nottingham Vet School, said: "It appears that veterinarians’ awareness of pain in cattle and willingness to use analgesics in general has increased over the last decade. However, whilst this should be commended, the apparent lack of use of appropriate analgesia specifically in calves undergoing routine husbandry procedures such as castration and disbudding requires urgent action. I am delighted that the findings of Nottingham University’s study support BVA/BCVA’s statement."
BVA and BCVA’s joint position paper on Analgesia in calves can be found at: https://www.bva.co.uk/uploadedFiles/Content/News,_campaigns_and_policies/Policies/Ethics_and_welfare/Analgesia%20in%20calves%20BVA%20branded.pdf
Photo: A calf in England, New Forest national park. Jim Champion. Wikipedia.